Skip to main content
. Author manuscript; available in PMC: 2009 Feb 1.
Published in final edited form as: Contraception. 2007 Dec 21;77(2):84–90. doi: 10.1016/j.contraception.2007.10.002

Table 3.

Proportion of subjects with HIV RNA levels <400 copies/mL and median CD4+ cell counts at each sampling

HIV RNA < 400 copies/mL Control* n=16 Nelfinavir n= 21 Efavirenz n= 17 Nevirapine n= 16
Baseline 7/15 (47%) 19/21 (90%) 16/17 (94%) 13/16 (81%)
Week 2 5/14 (36%) 15/21 (71%) 16/17 (94%) 11/13 (85%)
Week 4 7/16 (44%) 12/19 (63%) 16/17 (94%) 14/16 (88%)
Week 8 6/13 (46%) 13/16 (81%) 15/16 (94%) 8/10 (80%)
Week 12 6/15 (40%) 15/17 (88%) 15/16 (94%) 12/12 (100%)
Median CD4+ cell count (cells/uL)
Baseline 704 718 725 620
Week 4 692 620 650 671
Week 12 668 702 774 740
*

Women in the control arm were on no ARVl therapy or on NRTI only. Women in all other arms were on two or more nucleoside agents along with the drug listed.

No significant differences were seen between visits within each arm or in the group overall.